Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Conditions: Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma Interventions: Drug: Metabolically Armed CD19 CAR-T cells Sponsors: The Children ' s Hospital of Zhejiang University School of Medicine; Leman Biotech Co., Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biotechnology | Cancer & Oncology | Children | Hematology | Hospitals | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Research